Clinical trials: Resolution
Epilepsy
Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution
The purpose of this observational study is to broaden the knowledge of the known safety and efficacy profile of Keppra® (Levetiracetam) oral solution in epileptic infants younger than 12 months when treated according to routine…
- Trial name
- NCT01210690
- Where
- 27 sites in France, Germany and 5 more
- Volunteers
- 101 people
- Sponsor
- UCB Pharma
Seborrheic Keratosis
A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
This is a randomized, double-blind, vehicle-controlled, parallel group study of A-101 Solution 40% compared with Vehicle Solution.
- Trial name
- NCT02667236
- Testing
- A-101 Solution, Vehicle Solution
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Aclaris Therapeutics, Inc.
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
This study will be conducted to evaluate the safety, pharmacokinetics (PK), and efficacy of adjunctive GWP42003-P in participants < 2 years of age with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS), or Dravet…
- Conditions
- Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
- Trial name
- NCT04485104
- Testing
- GWP42003-P
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Vitiligo
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.
- Trial name
- NCT03468855
- Testing
- ATI-50002 topical solution
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aclaris Therapeutics, Inc.
Bronchiolitis
Inhaled Hypertonic Saline Use in the Emergency Department to Treat Acute Viral Bronchiolitis
Acute viral bronchiolitis is an extremely common childhood disease, responsible for approximately 17% of childhood admissions to hospital per year, with an annually cost that reaches U$ 500 million.
- Trial name
- NCT02045238
- Testing
- Hypertonic Saline, Chest X-Ray, Respiratory virus screening test
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- University of Sao Paulo
Healthy
A Study of Injections of LY3074828 in Healthy Participants
The purpose of this study is to learn about the effects of LY3074828 when given as an injection just under the skin by two different devices. The study will last about 12 weeks for each participant.
- Trial name
- NCT03886948
- Testing
- LY3074828, Pre-filled syringe (PFS), Autoinjector (AI)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dementia, Mental Health
Compass for Care: A Theory-driven Mobile Solution to Promote Well-being Among Caregivers of Individuals With ADRD
In the US, the over 11 million Americans currently providing unpaid care to a family member, relative, or friend with Alzheimer's disease or a related dementia (ADRD) are over 6 times more likely than the general population to…
- Trial name
- Compass4Care (NCT06249139)
- Testing
- Compass for Care (Well-being intervention), Compass for Care (Safety intervention)
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Pro-Change Behavior Systems
Dry Eye Disease
Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
This is a phase 2, multi-center, double-masked, randomized, vehicle-controlled, dose-response, parallel-group study designed to evaluate the safety and tolerability and ocular efficacy of SY-201 Ophthalmic Solution versus vehicle…
- Trial name
- NCT05370495
- Testing
- SY-201 Ophthalmic Solution 2.0%, SY-201 Ophthalmic Solution 1.0%, SY-201 Ophthalmic Solution 0.5%
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Seinda Pharmaceutical Guangzhou Corporation
Chronic Obstructive Pulmonary Disease - COPD
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
- Trial name
- NCT02796651
- Testing
- Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Formoterol fumarate (12 μg)
- Where
- 20 sites in United States
- Volunteers
- 132 people
- Sponsor
- AstraZeneca
Ocular Discomfort
A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution
The objective of this study is to evaluate the clinical performance of Bausch \& Lomb investigational Multi-Purpose Solution compared to Ciba Vision Multi-Purpose Solution when used by wearers of silicone hydrogel or Group IV…
- Trial name
- NCT01024751
- Testing
- Bausch & Lomb Multi-Purpose Solution, Ciba's Multi-Purpose Solution
- Where
- United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular…
- Trial name
- NCT03284853
- Testing
- Netarsudil/Latanoprost 0.02%/0.005%, GANFORT®
- Where
- 68 sites in Austria, Belgium and 9 more
- Volunteers
- 436 people
- Sponsor
- Aerie Pharmaceuticals
Hypogonadism
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
This study will evaluate if testosterone solution can raise testosterone hormone levels into the normal range after treatment for up to 9 Weeks, in those participants with a documented history of subtherapeutic levels [total…
- Trial name
- NCT01893281
- Testing
- Topical Testosterone Solution
- Where
- 21 sites in United States
- Volunteers
- 78 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
The purpose of this study is to assess the oral bioavailability of Apixaban solution formulation (Treatment B, 10 mg as 25 mL x 0.4 mg/mL) relative to Apixaban tablets (Treatment A, 10 mg as 2 x 5 mg tablets) in healthy subjects.
- Trial name
- NCT02034565
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cystic Fibrosis, Burkholderia Infections
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection
The purpose of this research study was to determine if an experimental drug called Aztreonam for Inhalation Solution (AZLI) was safe and effective to treat Burkholderia lung infections in patients with cystic fibrosis (CF).
- Trial name
- NCT01059565
- Testing
- AZLI
- Where
- 35 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Gilead Sciences
Healthy
A Study of Two Formulations of LY3074828 in Healthy Participants
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations.
- Trial name
- NCT03662100
- Testing
- LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dry Eye
Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)
The objective of this study is to compare the safety and efficacy of YP-P10 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT05467293
- Testing
- 0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 257 people
- Sponsor
- Yuyu Pharma, Inc.
Glaucoma
A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma
The purpose of this study is to assess the safety and efficacy of a new formulation of bimatoprost ophthalmic solution compared to timolol ophthalmic solution in the treatment of paediatric patients with glaucoma.
- Trial name
- NCT01426113
- Testing
- bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle
- Where
- 9 sites in United States, France and 5 more
- Volunteers
- 6 people
- Sponsor
- Allergan
Sickle Cell Disease, Leg Ulcers
Resolution of Sickle Cell Leg Ulcers With Voxelotor
This study is a Phase 3, multicenter, randomized, placebo-controlled study to evaluate the efficacy of voxelotor and standard of care for the treatment of leg ulcers in participants with sickle cell disease.
- Trial name
- RESOLVE (NCT05561140)
- Testing
- Voxelotor Oral Tablet
- Where
- 23 sites in Brazil, Kenya and 1 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
Seborrheic Keratosis (SK)
Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.
- Trial name
- NCT01986920
- Testing
- A-101 25%, A-101 32.5%, A-101 40%
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Aclaris Therapeutics, Inc.
Healthy Volunteers
Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
The purpose of this study is to assess the bioavailability of Apixaban solution administered through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to Apixaban solution administered orally in healthy…
- Trial name
- NCT02034578
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb